Inovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen
PLYMOUTH MEETING, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the company is more than doubling study enrollment to further characterize and identify in humans the most optimal immunization regimen …